Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients

NCT04393311 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Discontinuation of drug candidates

Conditions

COVID-19

Interventions

DRUG: Ulinastatin
DRUG: Placebo

Sponsor

Stanford University